Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Accord Healthcare, having received final FDA approval, is launching additional strengths of Hydroxychloroquine Sulfate tablets in doses of 100mg, 300mg and 400mg. Hydroxychloroquine is the generic version of Plaquenil® and is primarily used to treat rheumatoid arthritis, lupus and malaria.
read more
Modra Pharmaceuticals announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to the standard-of-care, the IV chemotherapy docetaxel.
read more
Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal®), and has begun commercialization activities.
read more
Enteris BioPharma, Inc., a biotechnology company developing drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, provided an update on its oral feasibility programs involving the company's Peptelligence® and ProPerma® oral peptide and small molecule delivery technologies.
read more
Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine.
read more
The global gummy vitamins market reached a value of US$ 6.4B in 2021. Looking forward, the publisher expects the market to reach US$ 8.6 Billion by 2027, exhibiting a CAGR of 5.31% during 2022-2027.
read more
Avion Pharmaceuticals announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided.
read more
The global probiotics market size is expected to reach $111.21B by 2030, according to a new study by Grand View Research, Inc.
read more
Theramex, a global pharmaceutical company specializing in women’s health, has entered into a licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialize and launch Linzagolix, an oral GnRH antagonist.
read more
DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, announced that Martti Hedman has been appointed as the new Chief Executive Officer.
read more
An investment consortium led by Signet Healthcare Partners, Bionpharma, Inc and GMS Capital Partners LLC announced it has formed Pharma Nobis, LLC (the “Company”) to acquire Fagron’s US contract manufacturing business.
read more
Ascletis Pharma Inc. announced the approval of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
read more
Varsity Pharmaceuticals, a biopharmaceutical company developing small molecule therapies that target treatment-resistant cancers, announced that it has secured exclusive rights from Dana-Farber Cancer Institute to develop and commercialize Novobiocin, a potential first-in-class DNA polymerase theta inhibitor for the treatment of Homologous ...
read more
In early 2022, Titanium Dioxide will be banned as a food additive in the EU, with additional regulations expected in other regions. Designed as a replacement for coatings containing TiO2, VIVACOAT® free offers customized solutions for both white and dark tablet cores.
read more
APNAR Pharma LP (APNAR), headquartered in Chino, CA, has acquired East Windsor, NJ-based Aurex Laboratories (Aurex) for an undisclosed amount.
read more